Form 4: Nuvation Bio Inc. Director Cui Xiangmin Reports Acquisition of Shares Following Merger

Director Cui Xiangmin reports acquiring shares of Nuvation Bio Inc. through entities associated with Decheng Capital, following a merger with AnHeart Therapeutics Ltd.

Summary

• Cui Xiangmin, a director of Nuvation Bio Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The filing pertains to shares acquired as a result of the merger between Nuvation Bio Inc. and AnHeart Therapeutics Ltd., completed on April 9, 2024.
• Cui Xiangmin's ownership is indirect, held through various Decheng Capital entities: Decheng Capital China Life Sciences USD Fund III, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and Decheng Anbio Limited.
• The total shares acquired indirectly amount to 314,106 shares through Decheng Capital China Life Sciences USD Fund III, 1,675,236 shares through Decheng Capital Global Healthcare Fund (Master), LP, and 4,183,002 shares through Decheng Anbio Limited.
• These shares were received in exchange for Series A and B Preferred shares of AnHeart Therapeutics as part of the merger agreement.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to a merger. The sentiment is neutral as it simply reports facts, but the merger itself could be viewed positively by investors.

Industry Context

Form 4 filings are standard practice when insiders of a company, such as directors or officers, have a transaction involving the company's securities, providing transparency to the market.

Stakeholder Impact

• Shareholders may be interested in the increased holdings of a director, potentially signaling confidence in the company's future.

Key Dates